🟢 Indaptus Therapeutics is trading 5.6% up in pre-market with no clear company-specific catalyst

Indaptus Therapeutics is trading at $3.75, up 5.63%, with no fresh company-specific announcement identified to explain the move.

• The stock closed at $3.55 on September 18, 2026.
• Financing announced September 8 involved approximately $24.0 million in gross proceeds but is stale context, not a clear catalyst.
• Broader risk-on sentiment may be supporting the move, with major U.S. indices up more than 0.5% in pre-market trading; confidence remains low.